Skip to main content

Manuel Comabella Lopez

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia
Manuel Comabella Lopez

Manuel Comabella Lopez

Manuel Comabella Lopez

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

From 1996 to 1998, Dr. Manuel Comabella was a Research Fellow in Neuroimmunology at the Center for Neurologic Diseases, Brigham and Women´s Hospital, in Boston. In 2010 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. In 2011 was awarded by the Spanish Society of Neurology (SEN) with the Biogen Idec Prize to the best publication on demyelinating disorders. In 2013 was awarded by the SEN with the Novartis Prize to the best oral communication and the best publication on demyelinating disorders. In 2014 received the Neurological Disorders Award, scientific modality, granted by the SEN. In 2016 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. From 2018 to 2020, Dr. Manuel Comabella was a collaborator of the Biomedicine area at the Division of Coordination, Evaluation and Scientific and Technical Follow-up of the State Research Agency, Ministry of Science, Innovation and Universities.

Dr. Manuel Comabella is member of the Editorial Board of Journal of Neuroimmunology and Multiple Sclerosis Journal, member of the Board of the ESNI (European School of Neuroimmunology), and member of the Strategic Group of the IMSGC (International Multiple Sclerosis Genetics Consortium). He is coauthor of 297 documents indexed in MedLine (Scopus: 12916 total citations, with h-index of 54). Dr. Manuel Comabella's research interest lies in the identification of biomarkers related with different aspects of multiple sclerosis and the development of new therapeutic strategies for the disease.

Projects

Immunogenicity: assesing the clinical relevance and risk minimization of antibodies to biopharmaceuticals. IMI Grant Agreement nº 115303

IP: Manuel Comabella Lopez
Collaborators: Carmen Tur Gomez, Xavier Montalban Gairín, Nicolás Miguel Fissolo
Funding agency: The Innovative Medicines Initiative
Funding: 464328
Reference: ABIRISK_IMI2010
Duration: 01/03/2012 - 27/02/2018

Estudio de la heterogeneidad en la susceptibilidad a la muerte celular por apoptosis en pacientes con esclerosis múltiple: búsqueda de dianas terapéuticas

IP: Manuel Comabella Lopez
Collaborators: -
Funding agency: Fundación Alicia Koplowitz
Funding: 75000
Reference: FAK-2010-03
Duration: 01/10/2010 - 31/03/2013

Búsqueda de marcadores de bioactividad del interferón-beta alternativos a la proteína MXA

IP: Manuel Comabella Lopez
Collaborators: Sunny Malhotra Sareen, Xavier Montalban Gairín
Funding agency: Fundación Merck Salud
Funding: 20000
Reference: MERCK-2009-05
Duration: 01/04/2010 - 31/03/2011

Validación de marcadores biológicos asociados con la conversión a esclerosis múltiple en pacientes con sínddromes clínicos aislados

IP: Manuel Comabella Lopez
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI09/00705
Duration: 07/09/2009 - 06/09/2013

Related news

The second edition of the AI ​​Day served to share knowledge, reflect and chart the future of artificial intelligence applied to research and health.

The Barcelona Risk Score is a flexible, generalisable clinical tool that will play a key role in selecting the most effective treatment for each person with multiple sclerosis

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Related professionals

Ariadna Garcia Rodriguez

Ariadna Garcia Rodriguez

Research technician
Childhood Cancer and Blood Disorders
Read more
Aitana Diaz Vazquez

Aitana Diaz Vazquez

Research technician
Clinical and Translational Bioinformatics
Read more
Santiago Ramon y Cajal Agüeras

Santiago Ramon y Cajal Agüeras

Head of group
Translational Molecular Pathology
Read more
Ester Serrano I Porras

Ester Serrano I Porras

Research technician
Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.